Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|June 14, 2019
Sphere Fluidics Secures a Total of $4.8 million in Funding
Author(s)Pharmaceutical Technology Editors
Sphere Fluidics has secured a total of $4.8 million (£3.7 million) in investment after closing its additional tranche investment work $2.9 million (£2.2 million).
Advertisement
Sphere Fluidics, which commercializes single-cell analysis systems, has secured a total of $4.8 million (£3.7 million) in investment after closing its additional tranche investment worth $2.9 million (£2.2 million).
The funding, which was led by Greenwood Way Capital, will be used as working capital for the company’s single-cell analysis system (Cyto-Mine), expansion of the company facility in the United Kingdom, and expansion of personnel with the opening of a new United States Sales Office and Demo Lab.
“We are delighted to raise this additional funding. Due to our over-subscribed investment round earlier this year, we decided to add on a second tranche to accommodate the additional interest,” said Frank F Craig PhD MBA, CEO, Sphere Fluidics, in a June 10, 2019 press release. “We are currently recruiting and looking at prospective new facilities in the UK and California to support the growth of our commercial and scientific activities.”
“We are very pleased to have been able to assist Sphere Fluidics once again and to have introduced them to suitable investors for their various funding stages,” added Ian Leigh, founder, Greenwood Way Capital. “This was our fourth funding round with them. Our members range from high net worth individuals to large family offices, which have enabled us to support the company from its early stage investment rounds to the recent larger scale-up fundraising. It has been exciting to have worked with such a professional team developing such a unique technology.”
Source:
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
3
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
4
Complying with International Pharmacopoeias
5